Compare EXEL & AR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EXEL | AR |
|---|---|---|
| Founded | 1994 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 11.4B |
| IPO Year | 2000 | 2013 |
| Metric | EXEL | AR |
|---|---|---|
| Price | $50.03 | $36.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 16 |
| Target Price | $46.50 | ★ $47.13 |
| AVG Volume (30 Days) | 2.6M | ★ 4.1M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 57.95 | ★ 1027.78 |
| EPS | 0.79 | ★ 1.72 |
| Revenue | $452,477,000.00 | ★ $5,275,823,000.00 |
| Revenue This Year | $13.61 | $29.74 |
| Revenue Next Year | $13.13 | $5.07 |
| P/E Ratio | $62.76 | ★ $21.51 |
| Revenue Growth | N/A | ★ 21.97 |
| 52 Week Low | $33.76 | $29.10 |
| 52 Week High | $51.63 | $45.75 |
| Indicator | EXEL | AR |
|---|---|---|
| Relative Strength Index (RSI) | 60.47 | 44.40 |
| Support Level | $40.42 | $35.47 |
| Resistance Level | $51.63 | $38.18 |
| Average True Range (ATR) | 1.67 | 1.01 |
| MACD | 0.06 | 0.06 |
| Stochastic Oscillator | 79.07 | 34.35 |
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Antero Resources is an exploration and production firm whose operations represent a pure play in the Marcellus Shale, located in northern West Virginia. The company started in 2002 as an E&P focused on the Barnett Shale (Fort Worth, Texas). Antero redefined itself in Appalachia's Marcellus Shale in 2005. In 2012, shortly before Antero's 2013 IPO, Antero Midstream Partners was formed to handle the company's rapidly growing gas volumes. In 2026, the firm narrowed its focus further by selling its Ohio Utica assets and using the proceeds to acquire additional Marcellus acreage from HG Energy. Just over half of its production and earning power is tied to natural gas, with the remainder mostly NGLs, where it holds a leading position, and some crude oil.